The market has treated Genmab like a growth biotech with questions attached. The stock sits at DKK2,011 after a strong 90 day run of about 23%, and today’s Q2 print gives investors fresh numbers to test that view.
The headline is simple. Genmab just delivered Q2 2026 total revenue of US$1.16b with net income of US$303m and basic earnings per share of US$4.94. That is the core of the story investors will weigh against a higher than peer P/E multiple and the company’s ambitious late stage oncology pipeline.
Is Genmab’s higher-than-peer P/E a hint that the market has already priced in this earnings profile, or does the supplied DCF suggest a mispriced opportunity for CPSE:GMAB? Compare the current share price against the supplied fair-value estimate on our valuation analysis for Genmab
Q2 2026 Earnings Summary
- Total Revenue, Q2 2026 vs. Q2 2025: US$1,155m vs. US$925m (up 24.9%)
- Net Income, Q2 2026 vs. Q2 2025: US$303m vs. US$336m (down 9.8%)
- Basic EPS, Q2 2026 vs. Q2 2025: US$4.94 vs. US$5.44 (down 9.2%)
- R&D Pipeline, Q2 2026 vs. Q2 2025: Phase I products 7 vs. 6; Phase II products 4 vs. 7; Phase III products 9 vs. 16 (fewer late stage assets reported in this snapshot)
Prefer clean charts over another wall of earnings tables and pipeline figures for Genmab? See the full visual breakdown of the stock, including how its valuation compares with recent results, in our company report for Genmab.
Genmab bull case leans on execution milestones
Bulls argue Genmab is turning late stage science into a durable commercial engine. The latest results provide some concrete proof points. H1 2026 revenue grew 25% with adjusted operating profit up 18%. Proprietary product sales reached US$396m, with EPKINLY at US$312m and Tivdak at US$84m. That supports the idea that Genmab is no longer just a royalty story. The EPCORE DLBCL 4 Phase 3 win, plus European approval of TEPKINLY in follicular lymphoma, shows the epcoritamab franchise is hitting key clinical and regulatory milestones on time. Management backed this up by raising 2026 revenue guidance to a range of US$4.3b to US$4.5b and lifting operating profit guidance while only modestly increasing OpEx. For the bullish narrative, this combination of clinical success, broader geographies and higher owned sales is the operational progress that was hoped for.
Bear case flags dependence and pipeline growing pains
The cautious view is that Genmab is still heavily exposed to partnered royalties and a stretched pipeline. Recent numbers do acknowledge that risk. Management stated that about half of H1 revenue growth came from Johnson & Johnson’s DARZALEX, reinforcing reliance on a single high margin stream. Net income in Q2 fell from US$336m to US$303m and basic EPS moved from US$5.44 to US$4.94 even as revenue rose, which supports concerns about the cost of scaling commercial infrastructure and R&D. The pipeline snapshot also shows fewer Phase III assets than a year ago, which fits with worries after HexaBody discontinuations that not every program will progress cleanly. Raised OpEx guidance to fund two new petosemtamab Phase IIIs and the Merus integration underlines that higher spending is needed before any offset to eventual DARZALEX pressure becomes visible in earnings.
After profit margins compressed and debt coverage looks weaker, it is worth asking if this is only the beginning. Review our risk analysis for Genmab which shows 2 important warning signs.Stay Ahead With Simply Wall St
If Genmab’s mix of higher P/E, shifting pipeline and updated guidance has your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price against fair value and wait for a setup that suits you. After you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key fundamental and earnings alerts that matter to your holdings. For the longer term, plug into thousands of investor views through the Community to see how others are interpreting new data points and stock moves. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market rather than reacting to it late.
Seeking Alternatives Beyond Genmab?
Fresh ideas often break out quietly while attention stays locked on familiar stocks. Use that window before momentum is fully caught by the crowd and act now.
- Spot early momentum in smaller companies that already generate cash and avoid constant capital raises by scanning 68 profitable AI stocks that aren't just burning cash before they stop flying under the radar for now.
- Balance Genmab exposure with sturdier businesses by checking the curated list of solid balance sheet and fundamentals stocks (422 results) while these setups still look appealing before the crowd prices in their strength.
- Target potential cash return and price stability in one move by reviewing the hand picked 440 dividend fortresses before yields compress and these opportunities start dropping off income radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com